Sanofi and Regeneron announce regulatory and clinical update for Zaltrap® (aflibercept)

Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the FDA has granted Priority Review of the Biologics License Application (BLA) for the investigational agent Zaltrap® (aflibercept) concentrate for solution for infusion in combination with the irinotecan-fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-containing regimen...

Read the full story >>

Abbott receives approval for next-generation XIENCE PRIME™ drug eluting stent in Japan
Abbott announced it has received approval from the Japanese MHLW...

Roche disappointed with ISS recommendation
Roche released the following statement in response to a report issued by Institutional Shareholder Services...

FDA approves Amyvid™
Amyvid is the first and only radioactive diagnostic agent approved for PET imaging of beta-amyloid neuritic plaques in the living brain...

FDA decides Teva is sole first-to-file on Provigil®
Teva Pharmaceuticals USA, is sole first-to-file for both Orange Book patents listed for Provigil® (modafinil)...

UCB and Amgen initiate sclerostin antibody Phase 3 program in patients with Postmenopausal Osteoporosis
The start of sclerostin antibody Phase 3 clinical trial program announced...

GSK receives further data from phase lll studies of albiglutide in type 2 diabetes
Data from seven studies support progression towards regulatory filings...

Teva announces launch of generic Avapro® and generic Avalide® in the United States
180-day period of marketing exclusivity awarded...

Novartis QVA149 Phase III COPD studies meet primary endpoints
QVA149 efficacy, safety and exercise endurance primary endpoints all met...

Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV
SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir...

Efficacy and safety data for ZOSTAVAX®
Merck announced that data from the pivotal Phase III study with ZOSTAVAX® in adults ages 50 to 59 were published in the April 1 issue of Clinical Infectious Diseases...

Amgen and AstraZeneca announce collaboration
Collaboration comprises five monoclonal antibodies brodalumab (AMG 827) Phase 3 trial planned in 2012...

BASF and Catalent join forces to solve bioavailability challenges
Catalent Pharma Solutions and BASF have entered into a broad collaboration...

Lonza appoints Richard Ridinger as new CEO
At a meeting on 2 April 2012, the Board of Directors of Lonza elected Mr. Richard Ridinger as the new CEO of Lonza...

Tecan granted patent for revolutionary NanoQuant Plate™
The revolutionary design of Tecan’s NanoQuant Plate™ has been recognized with the granting of a new European patent...

Interview with Robert Mattes, Applications Scientist, FOSS NIRSystems
Freddy White, European Pharmaceutical Review speaks to Robert Mattes, Applications Scientist, FOSS NIRSystems...